Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week

KT-621 expected to start Phase 1 in the second half of 2024,
with Phase 1 data in the first half of 2025

WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the presentation of additional preclinical data for KT-621, a potent, selective, oral heterobifunctional degrader of STAT6, at the American Thoracic Society (ATS) Annual Meeting in San Diego, California. The featured data demonstrate activity of KT-621 comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the tested cytokines, chemokines, and cell infiltrates involved in TH2 inflammation in asthma. The Company shared additional new histology data showing amelioration of lung remodeling after low, daily oral doses of KT-621 that was comparable to dupilumab. These data highlight the compelling profile of KT-621 as a potential oral treatment for asthma and other TH2 respiratory diseases. Kymera intends to initiate Phase 1 testing for KT-621 in the second half of 2024 and expects data from the Phase 1 trial to be reported in the first half of 2025.

“Having advanced the first degrader into the clinic for immunological diseases with KT-474, we’re now focused on delivering additional oral small molecule degraders with biologics-like activity to help as many patients as possible with these conditions,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “KT-621 has the potential to address multiple TH2 immune-mediated diseases and overcome the limitations of existing technologies and agents, such as biologics and traditional small molecule inhibitors. We believe KT-621 can provide the convenience of a once daily oral medicine with the potential to deliver dupilumab-like activity in highly prevalent allergic diseases like asthma, and in doing so has the promise to transform current treatment paradigms and reach broader patient populations.”